Abstract 3231
Background
CT-guided percutaneous biopsy is a minimally invasive technique used for obtaining enough tissue samples in the diagnosis of pulmonary lesions. The common complications of CT-guided percutaneous lung biopsy include pneumothorax, hemoptysis. Coaxial technique makes it much easier to repeat sampling and obtain adequate specimens, still it makes no change to the high incidence of pneumothorax. Basic on the research De Filippoet al. had done about complications, we hypothesis that when the inner chuck of coaxial guiding needle was removed and the cutting needle was placed inside the guiding needle, the injection of a small amount of liquid (a mixture of lidocaine and hemocoagulase) through the syringe while withdraw of the guiding needle may help to prevent the incidence of pneumothorax for which close the needle track with liquid.
Methods
From August 24th, 2018 to April 1th ,2019, a total of 32 CT-guided percutaneous transthoracic biopsy procedures performed in 32 patients were retrospectively evaluated. The patients were divided into groups regarding the lesion from pleural surface: <30 mm or ≥ 30 mm. The rates of complications such as pneumothorax and pneumorrhagia were analyzed. And the complications were graded as mild/very mild, moderate, and severe. Different complications between the two groups were analyzed using Pearson’s Chi-squared test for categorical values.
Results
Pathology results were malignant in 28 patients (17 cases were adenocarcinoma), benign in 4 patients.7 cases (21.9%) happened pneumothorax (4 very mild pneumothorax, 2 mild pneumothorax, 1 moderate pneumothorax),13 cases (40.6%) happened pneumorrhagia (12 mild pneumorrhagia, 1 very mild pneumorrhagia). And there was no statistically significant between pneumothorax and the depth of lesion to pleural surface (P > 0.05).
Conclusions
Compared to co-axial technique only, CT-guided percutaneous lung biopsy using co-axial combined with "liquid withdraw" significantly reduced the incidence of pneumothorax, which has been confirmed what we found in earlier retrospective study. The new technique provided an more accurate, secure and reliable way to obtain adequate tissue samples in the diagnosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Comprehensive Cancer Center of Drum-Tower Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract